Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose:
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation resulting in the production of antinuclear and other autoantibodies, generation of circulating immune complexes, and activation of the complement system. The disease course of SLE is heterogeneous, affecting different individuals with a wide range of manifestations.
Recent genetic studies identified a group of type I Interferon-inducible genes (IFIGs) that are significantly upregulated in peripheral blood cells from SLE patients. IFIGs show expression of 5 types [Myxovirus resistance 1 (Mx1), Oligoadenylate synthetase (OAS)1, and Lymphocyte antigen 6 complex, locus E (Ly6e), Oligoadenylate synthetase–like (OASL), and Interferon-inducible protein (clone IFI-15K) (ISG15)] in peripheral blood sample from SLE patients.
The aim of the study was to assess the expression of type I IFIGs (LY6E) in patients with SLE. In addition, we evaluated the association of its levels with disease activity and/or severity, and laboratory markers.
Methods:
Peripheral blood sample were obtained from 40 SLE patients and 25 healthy donors and total RNA was extracted and reverse transcribed into complementary DNA. Level of expression of type I IFIGs (LY6E) was measured by real time polymerase chain reaction (PCR-RT), after which comparisons were performed between SLE patients and control individuals.
Disease status was assessed according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index.
Results:
Type I IFIGs (LY6E) was highly expressed in SLE patients compared with normal controls (P<0.000). Type I IFIGs (LY6E) was positively associated with the SLEDAI score (p<0.02). Elevated type I IFIGs (LY6E) was also associated with the presence of cumulative organ damage SLICC/ACR-Damage Index (P<0.01).
Type I IFIGs (LY6E) was positively correlated with anti–double-stranded DNA (anti-dsDNA) antibodies (P<0.01) and negatively correlated with C3 (P<0.03). LY6E expression levels was positively associated with proteinuria (P <0.009).
Conclusion:
Type I IFIGs (LY6E) was highly expressed in SLE patients, and higher expression of LY6E gene in SLE patients is closely correlated with disease activity, degree of organ damage, proteinuria, anti-dsDNA antibody and hypocomplementemia. Besides, its elevated level may predict SLE flares.
The data suggest that type I IFIGs (LY6E) may contribute to SLE pathogenesis and the finding of this study will shed new light on dysregulation of the immune system and the involvement of inflammation in the initiation and perpetuation of autoimmunity.
Disclosure:
E. Omran,
None;
T. M Khidre,
None;
E. Alkady,
None;
E. Mosaad,
None;
M. Hussein Abd Elsamea,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-of-interferon-inducible-gene-lymphocyte-antigen-6-complex-locus-e-in-systemic-lupus-erythematosus-patients-and-its-association-with-disease-activity/